DOT takes heat for drug testing certification delays
DOT Delay
DOT takes heat for drug testing certification delays
Trucking industry still waiting for oral fluid testing labs to be approved
WASHINGTON — Drug testing facilities that have invested in oral-fluid-based testing for motor carriers, airlines, railroads and pipeline operators are pushing back on a proposal by the U.S. Department of Transportation that would temporarily reinstate urine-testing requirements.
DOT’s notice of proposed rulemaking, published in December, would revise its May 2023 drug testing procedures final rule, which became effective in June 2023.
In the final rule, DOT codified a procedure requiring that an oral fluid test – rather than a urine test – be conducted in certain circumstances when an observed collection is required, for example, if the original sample was invalid without a medical explanation, or to satisfy a successful return to duty for a truck driver.
However, oral fluid testing cannot be implemented until the Department of Health and Human Services certifies at least two laboratories, one to serve as a primary laboratory and a second to serve as a split-specimen laboratory – something HHS has not yet been able to do.
“Because no oral fluid laboratories have been certified, it is not yet possible to comply with this provision,” DOT stated in its proposed rule.
To address the problem, DOT proposed amending its regulations to require the conduct of directly observed urine collections in those circumstances for an interim period.
“We intend this provision to require directly observed urine tests in situations where an oral fluid collection is required, but is not yet available, to be a temporary, short-term solution,” DOT stated. “This provision will sunset one year after HHS publishes a Federal Register notice that it certified the second oral fluid drug testing laboratory.”
DOT pointed out that the proposed rule “will not affect a significant number of drug tests, and as such, will not impose any significant costs or have any significant impacts on the DOT testing program.”
But others disagree, pushing back on the one-year sunset provision included in the proposed rule.
“We have spent quite a bit to get people trained and in new lab kits in preparation for the new regulation, and delaying this any further means return on these investments will be pushed back as well,” Indira Narinesingh, a principal with Occupational Health Solutions, a health care services company, told FreightWaves.
Her company works primarily in the oil and gas pipeline sector. However, “these concerns would apply equally with any of the [DOT] modalities,” Narinesingh said.
Article LINK : www.Freightwaves-com-cdn - John Gallagher - January 2025
—————————
While the DOT faces continued delays in rolling out oral fluid drug testing, non-DOT programs don’t have to wait.
By combining oral fluid point-of-care testing with Neopharma’s cutting-edge reader technology, employers can:
✅ Hire faster
✅ Save money
✅ Retain top talent
✅ Boost productivity
✅ Enhance compliance
✅ Streamline record-keeping
It’s time to rethink workplace drug testing as a tool for efficiency, safety, and employee well-being.
📩 Contact us today to see how Neopharma Technologies Limited can help your organization stay ahead of the curve: Info@neopharmatechnologies.com